APA (7th ed.) Citation

Leblond, V., Morel, P., Dilhuidy, M., Leleu, X., Soussain, C., Leprête, S., . . . Chevret, S. (2017). A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: Interest of addition of dexamethasone. Leukemia & Lymphoma, 58(11), 2615. https://doi.org/10.1080/10428194.2017.1307357

Chicago Style (17th ed.) Citation

Leblond, Véronique, et al. "A Phase II Bayesian Sequential Clinical Trial in Advanced Waldenström Macroglobulinemia Patients Treated with Bortezomib: Interest of Addition of Dexamethasone." Leukemia & Lymphoma 58, no. 11 (2017): 2615. https://doi.org/10.1080/10428194.2017.1307357.

MLA (9th ed.) Citation

Leblond, Véronique, et al. "A Phase II Bayesian Sequential Clinical Trial in Advanced Waldenström Macroglobulinemia Patients Treated with Bortezomib: Interest of Addition of Dexamethasone." Leukemia & Lymphoma, vol. 58, no. 11, 2017, p. 2615, https://doi.org/10.1080/10428194.2017.1307357.